Updated Jul 16, 2026 · Last SEC filing 2026-07-10
Immunovant, Inc. (IMVT) has filed 17 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-10. 1 Form 8-K material event filings were reported by IMVT in the last 90 days. 8 Form 144 notices of proposed sale were filed for IMVT stock. InsiderAlpha tracks every IMVT SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Biological Products, (No Diagnostic Substances) (SIC 2836) |
|---|---|
| SEC CIK | 0001764013 |
| Form 4 filings (90d) | 17 |
|---|---|
| Form 8-K filings (90d) | 1 |
| Form 144 notices (90d) | 8 |
| Latest Form 4 filing | 2026-07-10 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Van Tuyl Christopher | Chief Legal Officer | S — Open-market sale | 1.1K | $39.53 | $45K | SEC | |
| Stout Jay S | Chief Technology Officer | S — Open-market sale | 105 | $39.99 | $4K | SEC | |
| Gloria Melanie | Chief Operating Officer | S — Open-market sale | 106 | $39.99 | $4K | SEC | |
| Stout Jay S | Chief Technology Officer | S — Open-market sale | 1.9K | $39.53 | $75K | SEC | |
| Stout Jay S | Chief Technology Officer | S — Open-market sale | 1.4K | $39.53 | $55K | SEC | |
| Stout Jay S | Chief Technology Officer | S — Open-market sale | 77 | $39.99 | $3K | SEC | |
| Gloria Melanie | Chief Operating Officer | S — Open-market sale | 1.9K | $39.53 | $76K | SEC | |
| Van Tuyl Christopher | Chief Legal Officer | S — Open-market sale | 63 | $39.99 | $3K | SEC | |
| Venker Eric | Chief Executive Officer | S — Open-market sale | 3.1K | $38.48 | $119K | SEC | |
| Venker Eric | Chief Executive Officer | M — Option exercise | 92.2K | $14.46 | $1.33M | SEC | |
| Venker Eric | Chief Executive Officer | D — Derivative transaction | 86.6K | $38.14 | $3.30M | SEC | |
| Stout Jay S | Chief Technology Officer | S — Open-market sale | 33.3K | $38.18 | $1.27M | SEC | |
| Pande Atul | Director | M — Option exercise | 1.5K | $8.43 | $13K | SEC | |
| Girao Tiago | Chief Financial Officer | S — Open-market sale | 10.0K | $38.46 | $385K | SEC | |
| Van Tuyl Christopher | Chief Legal Officer | M — Option exercise | 17.8K | $15.20 | $271K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Immunovant, Inc. (IMVT). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Fromkin Andrew J. | 10 | $9.05M |
| Pande Atul | 9 | $376K |
| Stout Jay S | 7 | $1.75M |
| Gloria Melanie | 7 | $860K |
| Van Tuyl Christopher | 7 | $1.09M |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in IMVT insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live IMVT dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.